Note: Information in older articles may not be the latest.
AI & Your Health, plus New Hepatitis Strategies and more: Liver Health Session | Prison & IDUs | New Hepatitis Strategies | 10 Years of DAAs | How Hep B Became a Political Football | Hep B POCT | In Our Library | Contacts
Ten years ago, on 1 March 2016, Australia became the first country to publicly subsidise new direct-acting antiviral (DAA) hepatitis C treatments for the entire population, no matter their condition or location.
The success of this has been dramatic:
Announcing the $1 billion funding just before Christmas in 2015, the then Federal Minister for Health, Sussan Ley, described the listing of the drugs on the Pharmaceutical Benefits Scheme (PBS) as a “watershed moment”. Continue reading.
In this issue: Hep B Birth Dose | Jeff Steward Farewell | Spreading the Word | Hep D Basics | Closing the Gap in Practice | Reducing BBVs in Regional SA | Intertwined | Unsung Hep Hero | In Our Library | Contacts
Australia's leading hepatitis researchers and clinicians have released a joint statement backing ATAGI advice on hepatitis B vaccinations.
Recent changes to the processing of pathology reports for My Health Record has elevated the importance of pre-test counselling around implications of test results, where to go for further information, and confidentiality.
Hepatitis Australia and ASHM are urging Australians to maintain routine hepatitis B vaccinations for newborns.
Findings from the Australian Needle and Syringe Program (NSP) Survey 30-year National Data Report shows highly significant reductions in hepatitis C infections and high levels of treatment and cure among NSP clients. Nationally the proportion of respondents with active hepatitis C infection (HCV RNA positive) declined substantially, from 51% in 2015 to 8% in 2024.
Hepatitis Australia is calling for national roll out universal hepatitis B testing for people over the age of 25.In a statement issued 8 April, Hepatitis Australia CEO, Lucy Clynes, said universal testing for hepatitis B is the next crucial step in eliminating hepatitis B and reducing liver cancer.
South Australian pharmacists can now administer long-acting injectable buprenorphine bringing SA in line with other Australian jurisdictions.
In this issue: High Hep C Cure Rate among NSP Clients |A Call to Action for nurses and midwives | Hep C & Mental Illness: New Link discovered | How Hep B Research Helped when COVID-19 Hit | SA Nurses Say Get Tested | Can a Parent's HBV Affect Their Newborn's Heart? | In Our Library: Life after hepatitis C | Wait! There's more...
In this issue: Testing Saves Lives |Malhotra Syndrome - what is it? | What SA did during World Hep Day | DAA Hep C cure rates | Hep B treatment: good & bad news | Supporting families who support users | In Our Library
Every year, nearly 1000 people in Australia die from hepatitis B and C. Close to 300,000 are living with viral hepatitis. We have the tools to stop this - it's time for action.
